Multiple Myeloma FAQ
Multiple Myeloma FAQ
The questions on this page come after the medical ones have been answered — what treatment will cost, how long the patient will be away from home, which drugs can actually be given here, and what happens on return. They are answered separately on purpose, because myeloma is treated continuously over years rather than in a single episode, and the practical arrangements are what make that possible to sustain.
What treatment costs
Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on which parts of the pathway you need:
- Diagnosis and staging — the protein studies, the marrow examination with chromosome testing, and whole-skeleton imaging; modest individually, and the basis of everything that follows.
- Induction treatment — the largest drug cost in the first year, since it combines three classes plus an antibody, and the total is counted in cycles rather than doses.
- Stem cell collection and transplant — apheresis, cell processing and storage, the high-dose treatment, and several weeks of inpatient care with transfusion and anti-infective support.
- Maintenance treatment — a lower cost per month but continued over years, which is why it is worth asking for the monthly figure rather than only the induction estimate.
- Supportive treatment — bone-strengthening drugs, prophylaxis, growth factors and vaccinations; individually small, and a real part of the total over a long course.
How long you will need to stay
The length of a stay is determined by which phase of treatment you are in rather than by any general rule:
- Initial assessment — usually one to two weeks, because the protein studies, the marrow examination and the chromosome testing need time to be reported.
- Induction cycles — each cycle is given over a few days, with an interval of two to three weeks between cycles; many patients are treated as outpatients with short admissions rather than staying throughout.
- Transplant — several weeks in hospital, covering the high-dose treatment and the period during which the blood counts are low, followed by outpatient monitoring before travel is considered.
- Maintenance — no admission, since it is oral treatment taken at home with periodic blood tests, which many patients arrange locally.
Which medicines are available
Most medicines used in myeloma internationally are available here:
- Proteasome inhibitors — including the first-generation drug and the later ones used in relapse, with one of them favoured when kidney function is impaired.
- Immunomodulatory drugs — including the agent used as maintenance after transplant and the later generation used in relapsed disease.
- Monoclonal antibodies directed at CD38 — used in the first line in combination, and again in later lines.
- Bone-strengthening drugs — both the intravenous bisphosphonate and the alternative agent used when kidney function limits it.
- Bispecific antibodies and CAR T-cell therapy directed at BCMA — available for disease that has returned after several lines, subject to an assessment of suitability.
- Supportive medicines — infection prophylaxis, antivirals, growth factors, clot prevention and pain control; these are part of the regimen, not optional extras.
Sending records and receiving a written opinion
The most useful thing to send is the original documents rather than a summary:
- The protein studies with their values and units — electrophoresis and immunofixation reports, and the free light chain ratio with both values, at each time point rather than only the most recent.
- The marrow reports — the plasma cell proportion, the trephine description, and the FISH findings, since these set the risk group that affects how intensive treatment should be.
- The imaging report — whole-body low-dose CT, MRI or PET-CT as performed, with the number and sites of lesions.
- The treatment history — each combination given, the dates, the number of cycles, any dose reductions, and the response measured after each phase.
- Recent blood results — the full blood count, calcium, creatinine and albumin, which determine what can be given safely now.
Insurance and payment
Coverage for myeloma needs checking in more detail than for most conditions, because treatment continues over years:
- Check whether the policy covers treatment outside your country of residence before assuming it does, and whether prior authorisation is required for each phase.
- Check the outpatient drug cover specifically — continuous oral treatment is often handled differently from inpatient care, and it is where the long-run cost sits.
- Check the transplant provision, including cell collection, processing and storage, the admission itself, and the months of follow-up. These are frequently bundled or capped.
- Ask whether direct billing is available for your insurer, and request the documentation they require at the outset — a plan, an estimate and clinical justification take time to assemble.
After treatment, and back home
Because myeloma is managed over years, the handover document matters more here than in most conditions:
- A written summary of the treatment actually given — each drug, the cumulative dose, the cycles completed, and the response measured at the end of each phase.
- A monitoring schedule with defined intervals — which tests, at what intervals, and what change would prompt an earlier review.
- The prophylaxis plan — anti-infective medication, antivirals, clot prevention, and the vaccination schedule with the interval after treatment during which live vaccines are avoided.
- Long-term points to monitor — kidney function, bone health including a dental review before and during bone-strengthening treatment, blood counts on continuous treatment, and second cancers, which occur rarely and are one reason review continues.
- A named contact, for questions between visits and for a video review of results taken elsewhere.
Eating and daily life during treatment
No diet treats myeloma. What nutrition and daily life can do is support you through long-term treatment:
- Food safety matters more than food choice. During periods when the white cell count is low, avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood, and unwashed produce is a concrete protective measure.
- Adequate protein and calories to maintain weight, because weight loss affects how the next cycle is tolerated and because steroids can affect appetite and blood sugar.
- Fluid intake — drinking enough protects the kidney, which is the organ most at risk in this disease, and it is particularly important during treatment and in hot weather.
- Gentle activity and fall prevention — keeping muscles and balance working reduces fractures, while becoming inactive weakens both bone and muscle.
- Supplements — discuss them with the team first, because some interact with treatment, and a supplement marketed as protecting bone does not replace the medicine prescribed for that purpose.